Clinical Trials
29 trialsNCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT04809662 2024-11-07
Comparing Immune Responses to Topical Imiquimod
University of California, Davis
Terminated
NCT05740969 2023-02-23
PACKS
Zealand University Hospital
Phase 2 Unknown
NCT00189254 2022-02-07
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
Viatris Inc.
Completed
NCT00189267 2022-02-07
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
Viatris Inc.
Phase 2 Completed
NCT00294320 2022-02-07
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Viatris Inc.
Phase 3 Completed
NCT00777127 2022-02-07
LEIDA
Viatris Inc.
Phase 4 Completed
NCT01453179 2022-02-07
LEIDA 2
Viatris Inc.
Phase 4 Completed
NCT04842422 2022-01-11
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Medical University of Graz
Phase 4 Completed
NCT03914417 2021-01-20
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01686152 2020-11-24
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
Teva Pharmaceuticals USA
Phase 3 Completed
NCT00948428 2020-09-04
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldaraâ„¢ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT02120898 2019-12-13
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
Actavis Inc.
Phase 3 Completed
NCT02362152 2019-12-13
RAPID-ACT
LEO Pharma
Completed
NCT00814528 2018-09-10
Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses
University of Chicago
Phase NA Withdrawn
NCT02281682 2017-10-30
Akti
Maastricht University Medical Center
Phase 4 Unknown
NCT01538901 2017-09-12
AKtransplant
Medical University of Vienna
Phase 4 Terminated
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00828568 2014-01-28
Bioequivalence Study of Two Imiquimod Cream 5%
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01788007 2014-01-22
Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT01611480 2013-06-26
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Moberg Pharma AB
Phase 2 Completed
NCT01229319 2011-06-22
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Frankel, Amylynne, M.D.
Phase 4 Unknown
NCT00335179 2010-07-23
Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00116649 2010-07-20
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Graceway Pharmaceuticals, LLC
Phase 4 Completed
NCT00859105 2009-03-10
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis
Apotex Inc.
Phase 3 Completed
NCT00114023 2007-02-19
1-Year Follow up to the 1473-IMIQ Study
Graceway Pharmaceuticals, LLC
Completed
NCT00115154 2007-02-19
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
Graceway Pharmaceuticals, LLC
Phase 4 Completed
NCT00175643 2006-05-09
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
University of British Columbia
Phase 3 Completed